Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3793_Библиотеки_им_академика_М_И_Перельмана
.pdf
138.e4 PART III Coronary Artery Disease
https://t.me/medicina_free
90. Metoprolol in acute myocardial infarction. Mortality. The
MIAMI Trial Research Group. Am J Cardiol.
1985;56(14):15G–22G.
91. Group TS. Comparison of invasive and conservative strategies
after treatment with intravenous tissue plasminogen activator
in acute myocardial infarction. Results of the thrombolysis in
myocardial infarction (TIMI) phase II trial. N Engl J Med.
1989;320(10):618–627.
92. Dargie HJ. Effect of carvedilol on outcome after myocardial
infarction in patients with left-ventricular dysfunction: the
CAPRICORN randomised trial. Lancet.
2001;357(9266):1385–1390.
93. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect
of carvedilol after acute myocardial infarction: results of the
Carvedilol Post-Infarct Survival Control in Left Ventricular
Dysfunction (CAPRICORN) trial. J Am Coll Cardiol.
2005;45(4):525–530.
94. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral
metoprolol in 45,852 patients with acute myocardial infarction:
randomised placebo-controlled trial. Lancet.
2005;366(9497):1622–1632.
95. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on
mortality among high-risk and low-risk patients after
myocardial infarction. N Engl J Med. 1998;339(8):489–497.
96. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade
during and after myocardial infarction: an overview of the
randomized trials. Prog Cardiovasc Dis. 1985;27(5):335–371.
97. Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta
Blockade after myocardial infarction: systematic review and
meta regression analysis. BMJ. 1999;318(7200):1730–1737.
98. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM.
Effectiveness of beta-blocker therapy after acute myocardial
infarction in elderly patients with chronic obstructive
pulmonary disease or asthma. J Am Coll Cardiol.
2001;37(7):1950–1956.
99. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective
beta-blockers in patients with reactive airway disease: a
meta-analysis. Ann Intern Med. 2002;137(9):715–725.
100. Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial
effects of beta-blockers to angiotensin-converting enzyme
inhibitors in the Survival and Ventricular Enlargement (SAVE)
Study. SAVE Investigators. J Am Coll Cardiol.
1997;29(2):229–236.
101. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ.
Beta-adrenergic blocking agent use and mortality in patients
with asymptomatic and symptomatic left ventricular systolic
dysfunction: a post hoc analysis of the Studies of Left
Ventricular Dysfunction. J Am Coll Cardiol.
1999;33(4):916–923.
102. Spargias KS, Hall AS, Greenwood DC, Ball SG. beta blocker
treatment and other prognostic variables in patients with
clinical evidence of heart failure after acute myocardial
infarction: evidence from the AIRE study. Heart.
1999;81(1):25–32.
103. Radack K, Deck C. Beta-adrenergic blocker therapy does not
worsen intermittent claudication in subjects with peripheral
arterial disease. A meta-analysis of randomized controlled trials.
Arch Intern Med. 1991;151(9):1769–1776.
104. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Are
beta-blockers effective in elderly patients who undergo
coronary revascularization after acute myocardial infarction?
Arch Intern Med. 2000;160(7):947–952.
105. Jugdutt BI. Nitrates in myocardial infarction. Cardiovasc Drugs
Ther. 1994;8(4):635–646.
106. Diodati J, Theroux P, Latour JG, et al. Effects of nitroglycerin at
therapeutic doses on platelet aggregation in unstable angina
pectoris and acute myocardial infarction. Am J Cardiol.
1990;66(7):683–688.
107. Gorman MW, Sparks HV Jr. Nitroglycerin causes vasodilatation
within ischaemic myocardium. Cardiovasc Res.
1980;14(9):515–521.
108. Jugdutt BI. Myocardial salvage by intravenous nitroglycerin in
conscious dogs: loss of beneficial effect with marked
nitroglycerin-induced hypotension. Circulation.
1983;68(3):673–684.
109. Jugdutt BI, Warnica JW. Tolerance with low dose intravenous
nitroglycerin therapy in acute myocardial infarction. Am J
Cardiol. 1989;64(10):581–587.
110. Yusuf S, Collins R, MacMahon S, Peto R. Effect of intravenous
nitrates on mortality in acute myocardial infarction: an
overview of the randomised trials. Lancet.
1988;1(8594):1088–1092.
111. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate
singly and together on 6-week mortality and ventricular
function after acute myocardial infarction. Gruppo Italiano per
lo Studio della Sopravvivenza nell’infarto Miocardico. Lancet.
1994;343(8906):1115–1122.
112. ISIS-4: a randomised factorial trial assessing early oral
captopril, oral mononitrate, and intravenous magnesium
sulphate in 58,050 patients with suspected acute myocardial
infarction. ISIS-4 (Fourth International Study of Infarct
Survival) Collaborative Group. Lancet. 1995;345(8951):669–685.
113. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert
consensus document. Use of sildenafil (Viagra) in patients with
cardiovascular disease. American College of Cardiology/
American Heart Association. J Am Coll Cardiol.
1999;33(1):273–282.
114. Timmermans PB, Carini DJ, Chiu AT, et al. Angiotensin II
receptor antagonists. From discovery to antihypertensive drugs.
Hypertension. 1991;18(5 suppl):III136–III142.
115. Ferrario CM, Jessup J, Chappell MC, et al. Effect of
angiotensin-converting enzyme inhibition and angiotensin II
receptor blockers on cardiac angiotensin-converting enzyme 2.
Circulation. 2005;111(20):2605–2610.
116. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on
mortality and morbidity in patients with left ventricular
dysfunction after myocardial infarction. Results of the survival
and ventricular enlargement trial. The SAVE Investigators. N
Engl J Med. 1992;327(10):669–677.
117. St John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative
two-dimensional echocardiographic measurements are major
predictors of adverse cardiovascular events after acute
myocardial infarction. The protective effects of captopril.
Circulation. 1994;89(1):68–75.
118. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E.
Effect of captopril on progressive ventricular dilatation after
anterior myocardial infarction. N Engl J Med.
1988;319(2):80–86.
119. Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of
the angiotensin converting enzyme inhibitor enalapril on the
long-term progression of left ventricular dilatation in patients
with asymptomatic systolic dysfunction. SOLVD (Studies of
Left Ventricular Dysfunction) Investigators. Circulation.
1993;88(5 Pt 1):2277–2283.

CHAPTER 12 Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction 138.e5
https://t.me/medicina_free
120. Oosterga M, Voors AA, de Kam PJ, et al. Plasma angiotensinconverting enzyme activity and left ventricular dilation after
myocardial infarction. Circulation. 1997;95(12):2607–2609.
121. Swedberg K, Held P, Kjekshus J, et al. Effects of the early
administration of enalapril on mortality in patients with acute
myocardial infarction. Results of the Cooperative New
Scandinavian Enalapril Survival Study II (CONSENSUS II). N
Engl J Med. 1992;327(10):678–684.
122. Effect of ramipril on mortality and morbidity of survivors of
acute myocardial infarction with clinical evidence of heart
failure. The Acute Infarction Ramipril Efficacy (AIRE) Study
Investigators. Lancet. 1993;342(8875):821–828.
123. Ambrosioni E, Borghi C, Magnani B. The effect of the
angiotensin-converting-enzyme inhibitor zofenopril on
mortality and morbidity after anterior myocardial infarction.
The Survival of Myocardial Infarction Long-Term Evaluation
(SMILE) Study Investigators. N Engl J Med. 1995;332(2):80–85.
124. Investigators S, Yusuf S, Pitt B, et al. Effect of enalapril on
survival in patients with reduced left ventricular ejection
fractions and congestive heart failure. N Engl J Med.
1991;325(5):293–302.
125. Investigators S, Yusuf S, Pitt B, et al. Effect of enalapril on
mortality and the development of heart failure in asymptomatic
patients with reduced left ventricular ejection fractions. N Engl
J Med. 1992;327(10):685–691.
126. Group CTS. Effects of enalapril on mortality in severe
congestive heart failure. Results of the Cooperative North
Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J
Med. 1987;316(23):1429–1435.
127. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of
the angiotensin-converting-enzyme inhibitor trandolapril in
patients with left ventricular dysfunction after myocardial
infarction. Trandolapril Cardiac Evaluation (TRACE) Study
Group. N Engl J Med. 1995;333(25):1670–1676.
128. Oral captopril versus placebo among 13,634 patients with
suspected acute myocardial infarction: interim report from the
Chinese Cardiac Study (CCS-1). Lancet.
1995;345(8951):686–687.
129. Indications for ACE inhibitors in the early treatment of acute
myocardial infarction: systematic overview of individual data
from 100,000 patients in randomized trials. ACE Inhibitor
Myocardial Infarction Collaborative Group. Circulation.
1998;97(22):2202–2212.
130. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G. ACE
inhibitor use in patients with myocardial infarction. Summary
of evidence from clinical trials. Circulation.
1995;92(10):3132–3137.
131. Dickstein K, Kjekshus J, Group OSCotOS. Effects of losartan
and captopril on mortality and morbidity in high-risk patients
after acute myocardial infarction: the OPTIMAAL randomised
trial. Optimal Trial in Myocardial Infarction with Angiotensin
II Antagonist Losartan. Lancet. 2002;360(9335):752–760.
132. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan,
captopril, or both in myocardial infarction complicated by
heart failure, left ventricular dysfunction, or both. N Engl J
Med. 2003;349(20):1893–1906.
133. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone
on morbidity and mortality in patients with severe heart
failure. Randomized Aldactone Evaluation Study Investigators.
N Engl J Med. 1999;341(10):709–717.
134. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective
aldosterone blocker, in patients with left ventricular dysfunction
after myocardial infarction. N Engl J Med. 2003;348(14):
1309–1321.
135. Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death
in patients with myocardial infarction and left ventricular
dysfunction, heart failure, or both. N Engl J Med.
2005;352(25):2581–2588.
136. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an
implantable cardioverter-defibrillator after acute myocardial
infarction. N Engl J Med. 2004;351(24):2481–2488.
137. Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality
30 days after randomization following acute myocardial
infarction in patients with left ventricular systolic dysfunction
and heart failure. J Am Coll Cardiol. 2005;46(3):425–431.
138. Pitt B, Gheorghiade M, Zannad F, et al. Evaluation of
eplerenone in the subgroup of EPHESUS patients with baseline
left ventricular ejection fraction <or=30percent. Eur J Heart
Fail. 2006;8(3):295–301.
139. Kidney Disease Outcomes Quality I. K/DOQI clinical practice
guidelines on hypertension and antihypertensive agents in
chronic kidney disease. Am J Kidney Dis. 2004;43(5 suppl
1):S1–S290.
140. Palmer BF. Managing hyperkalemia caused by inhibitors of the
renin-angiotensin-aldosterone system. N Engl J Med.
2004;351(6):585–592.
141. Israili ZH, Hall WD. Cough and angioneurotic edema
associated with angiotensin-converting enzyme inhibitor
therapy. A review of the literature and pathophysiology. Ann
Intern Med. 1992;117(3):234–242.
142. Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics
of angioedema associated with enalapril. Arch Intern Med.
2005;165(14):1637–1642.
143. Sondhi D, Lippmann M, Murali G. Airway compromise due to
angiotensin-converting enzyme inhibitor-induced angioedema:
clinical experience at a large community teaching hospital.
Chest. 2004;126(2):400–404.
144. Abdi R, Dong VM, Lee CJ, Ntoso KA. Angiotensin II receptor
blocker-associated angioedema: on the heels of ACE inhibitor
angioedema. Pharmacotherapy. 2002;22(9):1173–1175.
145. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A.
Angioedema associated with angiotensin-converting enzyme
inhibitor use: outcome after switching to a different treatment.
Arch Intern Med. 2004;164(8):910–913.
146. Dykewicz MS. Cough and angioedema from angiotensinconverting enzyme inhibitors: new insights into mechanisms
and management. Curr Opin Allergy Clin Immunol.
2004;4(4):267–270.
147. Muller JE, Morrison J, Stone PH, et al. Nifedipine therapy for
patients with threatened and acute myocardial infarction: a
randomized, double-blind, placebo-controlled comparison.
Circulation. 1984;69(4):740–747.
148. Goldbourt U, Behar S, Reicher-Reiss H, et al. Early
administration of nifedipine in suspected acute myocardial
infarction. The Secondary Prevention Reinfarction Israel
Nifedipine Trial 2 Study. Arch Intern Med. 1993;153(3):
345–353.
149. Effect of verapamil on mortality and major events after acute
myocardial infarction (the Danish Verapamil Infarction Trial
II–DAVIT II). Am J Cardiol. 1990;66(10):779–785.
150. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and
reinfarction in patients with non-Q-wave myocardial infarction.
Results of a double-blind, randomized, multicenter trial. N Engl
J Med. 1986;315(7):423–429.

138.e6 PART III Coronary Artery Disease
https://t.me/medicina_free
151. Held PH, Yusuf S. Effects of beta-blockers and calcium channel
blockers in acute myocardial infarction. Eur Heart J.
1993;14(supplF):18–25.
152. Investigators G. An international randomized trial comparing
four thrombolytic strategies for acute myocardial infarction. N
Engl J Med. 1993;329(10):673–682.
153. Alexander JH, Granger CB, Sadowski Z, et al. Prophylactic
lidocaine use in acute myocardial infarction: incidence and
outcomes from two international trials. The GUSTO-I and
GUSTO-IIb Investigators. Am Heart J. 1999;137(5):799–805.
154. MacMahon S, Collins R, Peto R, Koster RW, Yusuf S. Effects of
prophylactic lidocaine in suspected acute myocardial infarction.
An overview of results from the randomized, controlled trials.
JAMA. 1988;260(13):1910–1916.
155. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and
morbidity in patients receiving encainide, flecainide, or placebo.
The Cardiac Arrhythmia Suppression Trial. N Engl J Med.
1991;324(12):781–788.
156. Hjalmarson A, Herlitz J, Holmberg S, et al. The Goteborg
metoprolol trial. Effects on mortality and morbidity in acute
myocardial infarction. Circulation. 1983;67(6 Pt 2):I26–I32.
157. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult
advanced cardiovascular life support: 2015 American Heart
Association Guidelines Update for Cardiopulmonary
Resuscitation and Emergency Cardiovascular Care. Circulation.
2015;132(18 suppl 2):S444–S464.
158. Meine TJ, Roe MT, Chen AY, et al. Association of intravenous
morphine use and outcomes in acute coronary syndromes:
results from the CRUSADE Quality Improvement Initiative. Am
Heart J. 2005;149(6):1043–1049.
159. Hobl EL, Stimpfl T, Ebner J, et al. Morphine decreases
clopidogrel concentrations and effects: a randomized, doubleblind, placebo-controlled trial. J Am Coll Cardiol.
2014;63(7):630–635.
160. Silvain J, Storey RF, Cayla G, et al. P2Y12 receptor inhibition and
effect of morphine in patients undergoing primary PCI for
ST-segment elevation myocardial infarction. The PRIVATEATLANTIC study. Thromb Haemost. 2016;116(2):369–378.
161. Thomas MR, Morton AC, Hossain R, et al. Morphine delays the
onset of action of prasugrel in patients with prior history of
ST-elevation myocardial infarction. Thromb Haemost.
2016;116(1):96–102.
162. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or
reinfarction associated with the use of selective
cyclooxygenase-2 inhibitors and nonselective nonsteroidal
antiinflammatory drugs after acute myocardial infarction.
Circulation. 2006;113(25):2906–2913.
163. Antman EM, Bennett JS, Daugherty A, et al. Use of
nonsteroidal antiinflammatory drugs: an update for clinicians:
a scientific statement from the American Heart Association.
Circulation. 2007;115(12):1634–1642.
164. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive
compared with moderate lipid-lowering therapy on progression
of coronary atherosclerosis: a randomized controlled trial.
JAMA. 2004;291(9):1071–1080.
165. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very highintensity statin therapy on regression of coronary
atherosclerosis: the ASTEROID trial. JAMA.
2006;295(13):1556–1565.
166. Randomised trial of cholesterol lowering in 4444 patients with
coronary heart disease: the Scandinavian Simvastatin Survival
Study (4S). Lancet. 1994;344(8934):1383–1389.
167. Long-Term Intervention with Pravastatin in Ischaemic Disease
Study G. Prevention of cardiovascular events and death with
pravastatin in patients with coronary heart disease and a broad
range of initial cholesterol levels. N Engl J Med.
1998;339(19):1349–1357.
168. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin
on coronary events after myocardial infarction in patients with
average cholesterol levels. Cholesterol and Recurrent Events
Trial investigators. N Engl J Med. 1996;335(14):1001–1009.
169. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus
moderate lipid lowering with statins after acute coronary
syndromes. N Engl J Med. 2004;350(15):1495–1504.
170. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of
atorvastatin on early recurrent ischemic events in acute
coronary syndromes: the MIRACL study: a randomized
controlled trial. JAMA. 2001;285(13):1711–1718.
171. Stenestrand U, Wallentin L. Swedish Register of Cardiac
Intensive C. Early statin treatment following acute myocardial
infarction and 1-year survival. JAMA. 2001;285(4):430–436.
172. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering
therapy on early mortality after acute coronary syndromes: an
observational study. Lancet. 2001;357(9262):1063–1068.
173. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved
treatment of coronary heart disease by implementation of a
Cardiac Hospitalization Atherosclerosis Management Program
(CHAMP). Am J Cardiol. 2001;87(7):819–822.
174. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent
clinical trials for the National Cholesterol Education Program
Adult Treatment Panel III guidelines. Circulation.
2004;110(2):227–239.
175. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA
guideline on the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular risk in adults: a report of the
American College of Cardiology/American Heart Association
Task Force on Practice Guidelines. J Am Coll Cardiol.
2014;63(25 Pt B):2889–2934.
176. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added
to Statin Therapy after Acute Coronary Syndromes. N Engl J
Med. 2015;372(25):2387–2397.
177. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and
Clinical Outcomes in Patients with Cardiovascular Disease. N
Engl J Med. 2017;376(18):1713–1722.
178. Hirsh J. Heparin. N Engl J Med. 1991;324(22):1565–1574.
179. Turpie AG, Robinson JG, Doyle DJ, et al. Comparison of
high-dose with low-dose subcutaneous heparin to prevent left
ventricular mural thrombosis in patients with acute transmural
anterior myocardial infarction. N Engl J Med.
1989;320(6):352–357.
180. Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ. Heparininduced thrombocytopenia. J Am Coll Cardiol.
1998;31(7):1449–1459.
181. Gruel Y, Pouplard C, Nguyen P, et al. Biological and clinical
features of low-molecular-weight heparin-induced
thrombocytopenia. Br J Haematol. 2003;121(5):786–792.
182. Napolitano LM, Warkentin TE, Almahameed A, Nasraway SA.
Heparin-induced thrombocytopenia in the critical care setting:
diagnosis and management. Crit Care Med.
2006;34(12):2898–2911.
183. Mahaffey KW, Granger CB, Collins R, et al. Overview of
randomized trials of intravenous heparin in patients with acute
myocardial infarction treated with thrombolytic therapy. Am J
Cardiol. 1996;77(8):551–556.

CHAPTER 12 Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction 138.e7
https://t.me/medicina_free
184. Granger CB, Hirsch J, Califf RM, et al. Activated partial
thromboplastin time and outcome after thrombolytic therapy
for acute myocardial infarction: results from the GUSTO-I trial.
Circulation. 1996;93(5):870–878.
185. Vaitkus PT, Barnathan ES. Embolic potential, prevention and
management of mural thrombus complicating anterior
myocardial infarction: a meta-analysis. J Am Coll Cardiol.
1993;22(4):1004–1009.
186. Yusuf S, Mehta SR, Xie C, et al. Effects of reviparin, a lowmolecular-weight heparin, on mortality, reinfarction, and
strokes in patients with acute myocardial infarction presenting
with ST-segment elevation. JAMA. 2005;293(4):427–435.
187. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux
on mortality and reinfarction in patients with acute
ST-segment elevation myocardial infarction: the OASIS-6
randomized trial. JAMA. 2006;295(13):1519–1530.
188. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clotbound thrombin is protected from inhibition by heparinantithrombin III but is susceptible to inactivation by
antithrombin III-independent inhibitors. J Clin Invest.
1990;86(2):385–391.
189. White H. Hirulog, Early Reperfusion or Occlusion -2 Trial I.
Thrombin-specific anticoagulation with bivalirudin versus
heparin in patients receiving fibrinolytic therapy for acute
myocardial infarction: the HERO-2 randomised trial. Lancet.
2001;358(9296):1855–1863.
190. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin
during primary PCI in acute myocardial infarction. N Engl J
Med. 2008;358(21):2218–2230.
191. Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin
versus bivalirudin in primary percutaneous coronary
intervention (HEAT-PPCI): an open-label, single centre,
randomised controlled trial. Lancet. 2014;384(9957):1849–1858.
192. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of
coagulation mechanism in unstable angina and myocardial
infarction. Circulation. 1994;90(1):61–68.
193. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR.
Warfarin plus aspirin after myocardial infarction or the acute
coronary syndrome: meta-analysis with estimates of risk and
benefit. Ann Intern Med. 2005;143(4):241–250.
194. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus
warfarin compared to aspirin alone after acute coronary
syndromes: an updated and comprehensive meta-analysis of
25,307 patients. Eur Heart J. 2006;27(5):519–526.
195. Reeder GS, Lengyel M, Tajik AJ, et al. Mural thrombus in left
ventricular aneurysm: incidence, role of angiography, and
relation between anticoagulation and embolization. Mayo Clin
Proc. 1981;56(2):77–81.
196. Alexander JH, Lopes RD, James S, et al. Apixaban with
antiplatelet therapy after acute coronary syndrome. N Engl J
Med. 2011;365(8):699–708.
197. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in
patients with a recent acute coronary syndrome. N Engl J Med.
2012;366(1):9–19.
198. Mega JL, Braunwald E, Murphy SA, et al. Rivaroxaban in
patients stabilized after a ST-segment elevation myocardial
infarction: results from the ATLAS ACS-2-TIMI-51 trial
(Anti-Xa Therapy to Lower Cardiovascular Events in Addition
to Standard Therapy in Subjects with Acute Coronary
Syndrome-Thrombolysis In Myocardial Infarction-51). J Am
Coll Cardiol. 2013;61(18):1853–1859.
199. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel
with or without aspirin in patients taking oral anticoagulant
therapy and undergoing percutaneous coronary intervention:
an open-label, randomised, controlled trial. Lancet.
2013;381(9872):1107–1115.
200. Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in
Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med.
2016;375(25):2423–2434.
201. Six-month effects of early treatment with lisinopril and
transdermal glyceryl trinitrate singly and together withdrawn
six weeks after acute myocardial infarction: the GISSI-3 trial.
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto
Miocardico. J Am Coll Cardiol. 1996;27(2):337–344.
202. Pfeffer MA, Greaves SC, Arnold JM, et al. Early versus delayed
angiotensin-converting enzyme inhibition therapy in acute
myocardial infarction. The healing and early afterload reducing
therapy trial. Circulation. 1997;95(12):2643–2651.
203. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan
versus captopril in patients over 65 with heart failure
(Evaluation of Losartan in the Elderly Study, ELITE). Lancet.
1997;349(9054):747–752.
204. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of
candesartan, enalapril, and their combination in congestive
heart failure: randomized evaluation of strategies for left
ventricular dysfunction (RESOLVD) pilot study. The RESOLVD
Pilot Study Investigators. Circulation. 1999;100(10):1056–1064.
205. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan
compared with captopril on mortality in patients with
symptomatic heart failure: randomised trial–the Losartan Heart
Failure Survival Study ELITE II. Lancet.
2000;355(9215):1582–1587.
206. Cohn JN, Tognoni G, Valsartan Heart Failure Trial I. A
randomized trial of the angiotensin-receptor blocker valsartan
in chronic heart failure. N Engl J Med. 2001;345(23):1667–
1675.
207. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of
candesartan on mortality and morbidity in patients with
chronic heart failure: the CHARM-Overall programme. Lancet.
2003;362(9386):759–766.
208. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of
candesartan in patients with chronic heart failure and reduced
left-ventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-Added trial. Lancet.
2003;362(9386):767–771.
209. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan
in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial.
Lancet. 2003;362(9386):772–776.
210. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in
patients with chronic heart failure and preserved leftventricular ejection fraction: the CHARM-Preserved Trial.
Lancet. 2003;362(9386):777–781.

SECTION 2 Complications of Acute Myocardial Infarction
https://t.me/medicina_free
Postmyocardial Infarction Cardiogenic Shock
OUTLINE
Epidemiology, 139
Definition, 139
Etiology, 139
Incidence, 140
Pathogenesis, 140
Pathology, 140
Pathophysiology, 140
Clinical Presentation, 141
History and Physical Examination, 141
Electrocardiography and Laboratory
Testing, 142
Echocardiography, 142
Management, 142
General Measures, 142
Hemodynamic Monitoring, 142
Pharmacologic Support, 144
Mechanical Support, 145
Reperfusion Strategies, 147
Fibrinolytic Therapy, 147
Percutaneous Coronary Intervention, 148
Surgery, 149
New Approaches, 149
Prognosis, 149
Conclusion, 150
13
Eric R. Bates
Dramatic advances during the past several decades in diagnosing,
monitoring, and treating patients with acute myocardial infarction
(MI) have decreased hospital mortality rates by 50%. The
organization of coronary care units in the 1960s to treat lethal
arrhythmias1 and the development of fibrinolytic therapy in the
1980s to reduce infarct size
Cardiogenic shock, not arrhythmia, is the most common cause
of death in patients hospitalized with acute MI. Neither the
incidence nor the mortality rate associated with cardiogenic
shock has been reduced by modern cardiac intensive care unit
interventions, including vasopressor and inotropic drug infusions,
hemodynamic monitoring, and intraaortic balloon pump (IABP)
counterpulsation (Table 13.1).
has been demonstrated for patients who undergo successful
reperfusion with percutaneous coronary intervention (PCI) or
coronary artery bypass graft surgery (CABG).
reviews the epidemiology, pathogenesis, clinical presentation,
and current management of cardiogenic shock.
2–5
were the biggest breakthroughs.
6–12
However, a survival advantage
13–19
This chapter
EPIDEMIOLOGY
Definition
Circulatory shock is characterized by the inability of multiorgan
blood flow and oxygen delivery to meet metabolic demands.
Cardiogenic shock is a type of circulatory shock resulting from
severe impairment of ventricular pump function rather than
from abnormalities of the vascular system or blood volume. It
is important to separate the shock state, in which tissue perfusion
is inadequate, from hypotension, in which tissue metabolic
demands may be met by increasing cardiac output or decreasing
systemic vascular resistance. The diagnosis of cardiogenic shock
should include the following:
1. Systolic blood pressure less than 80 mm Hg without inotropic
or vasopressor support, or less than 90 mm Hg with inotropic
or vasopressor support, for at least 30 minutes
2. Low cardiac output (<2.0 L/min per m2) not related to
hypovolemia (pulmonary artery wedge pressure <12 mm
Hg), arrhythmia, hypoxemia, acidosis, or atrioventricular block
3. Tissue hypoperfusion manifested by oliguria (<30 mL/h),
peripheral vasoconstriction, or altered mental status
The failure to consistently define cardiogenic shock or to
hemodynamically confirm the presence of an elevated pulmonary
capillary wedge pressure and low cardiac index have previously
confused clinicians and confounded the literature.
Etiology
The most common cause of cardiogenic shock is acute MI.20
Often, anterior MI due to acute thrombotic occlusion of the left
139

CHAPTER 13 Postmyocardial Infarction Cardiogenic Shock 139.e1
https://t.me/medicina_free
Key Words
Cardiogenic shock
Myocardial infarction
Percutaneous coronary intervention

140 PART III Coronary Artery Disease
https://t.me/medicina_free
TABLE 13.1 Historical Milestones in
Cardiogenic Shock
1934 Fishberg et al.6 described the shock state as a peripheral
complication of myocardial infarction.
1942 Stead and Ebert
dysfunction.
1954
1967 Killip and Kimball
1968
1972
1973
1976
1980
1980
1982
1988
1999
CABG, Coronary artery bypass graft surgery; IABP, intraaortic balloon
pump; PTCA, percutaneous transluminal coronary angioplasty.
Griffith et al.8 used L-norepinephrine as pressor support.
care unit monitoring.
Kantrowitz et al.9 described the clinical use of the IABP.
Dunkman et al.10 demonstrated successful treatment with CABG.
Scheidt et al.11 showed no survival advantage with IABP.
Forrester et al.12 defined hemodynamic subsets using the
pulmonary artery catheter.
DeWood et al.13 showed a survival advantage with early CABG.
Mathey et al.14 demonstrated successful treatment with
fibrinolytic therapy.
Meyer et al.15 demonstrated successful treatment with PTCA.
Lee et al.16 showed a survival advantage with PTCA.
Hochman et al.
revascularization in the SHOCK trial.
7
attributed the shock state to extreme myocardial
1
showed no survival advantage with coronary
17–19
proved a survival advantage with
anterior descending artery results in extensive infarction. Alternatively, a smaller MI in a patient with borderline left ventricular
function may be responsible for insufficient cardiac output. Large
areas of ischemic nonfunctioning but viable myocardium
occasionally lead to shock in patients with MI. The delayed onset
of shock may result from reocclusion of a previously patent
infarct artery, infarct extension, or metabolic decompensation
of noninfarct-zone regional wall motion. Occasionally, right
ventricular MI from occlusion of a proximal large right coronary
artery in a patient with inferior MI is the cause.
21
Mechanical complications unrelated to infarct size account
for approximately 12% of cases. The papillary muscle of the
mitral valve may infarct or rupture, causing acute, severe mitral
regurgitation.22 Rupture of the interventricular septum causing
ventricular septal defect23 or rupture of the left ventricular free wall
producing pericardial tamponade24 also needs to be considered.
Other causes of cardiogenic shock are not emphasized in this
discussion. These include end-stage cardiomyopathy, myocardial
contusion, myocarditis, hypertrophic cardiomyopathy, valvular
heart disease, pericardial disease, right ventricular infarction,
and post-cardiopulmonary bypass.
Incidence
Before the recent emphasis on time to treatment and primary
PCI, the incidence of cardiogenic shock had remained unchanged
for over 25 years, with approximately 8% of patients with ST
elevation myocardial infarction (STEMI)
with non-STEMI
27,28
developing cardiogenic shock. The latter
group is more likely to have circumflex artery occlusion, comorbid
disease, and severe three-vessel disease or left main disease.28
Cardiogenic shock usually develops early after onset of symptoms,
with approximately half of the patients developing shock within
6 hours and 72% within 24 hours.29 Others first develop a preshock
25,26
and 2.5% of patients
state manifested by systemic hypoperfusion without hypotension.30
These patients benefit from aggressive supportive therapy and
revascularization; early intervention may abort the onset of
cardiogenic shock.
PATHOGENESIS
Pathology
The early development of cardiogenic shock is usually caused
by acute thrombosis of a coronary artery supplying a large
myocardial distribution, with no collateral flow recruitment.31
Frequently, this is the left anterior descending artery, although
shock may result from coronary thrombosis in other sites if
previous MI has occurred. Multivessel disease is present in twothirds of patients.
Autopsy studies have consistently shown that at least 40% of
the myocardium is infarcted in patients who die of cardiogenic
shock.33 Various ages of infarction reflect previous infarction,
reinfarction, or infarct extension.
The infarct border zone in patients without hypotension is
clearly demarcated. In patients succumbing to shock, however,
it is irregular, with marginal extension. Focal areas of necrosis
remote from the infarct zone are also present. These findings
result from progressive cell death due to poor coronary perfusion,
are reflected by prolonged release of cardiac enzymes, and
contribute to hemodynamic deterioration.
Pathophysiology
Progressive hemodynamic deterioration resulting in cardiogenic
shock results from a sequence of events (Fig. 13.1). A critical
amount of ischemic or necrotic myocardium decreases contractile
mass and cardiac output. When cardiac output is low enough
that arterial blood pressure falls, coronary perfusion pressure
decreases in the setting of an elevated left ventricular end-diastolic
pressure. The resulting reduction in coronary perfusion pressure
gradient from epicardium to endocardium exacerbates myocardial
ischemia, further decreasing left ventricular function and cardiac
output, perpetuating a vicious cycle. The speed with which
this process develops is modified by the infarct zone, remote
myocardial function, neurohumoral responses, and metabolic
abnormalities.
The infarct zone can be enlarged by reocclusion of a previously
patent infarct artery. Alternatively, infarct extension can result
from side branch occlusion from coronary thrombus propagation
or embolization or by thrombosis of a second stenosis stimulated
by low coronary blood flow and hypercoagulability. Infarct
expansion or aneurysm formation promotes left ventricular
dilation, which increases wall stress and oxygen demand in the
setting of decreased oxygen supply due to low cardiac output.
Preclinical and clinical studies
importance of hypercontractility of remote myocardial segments
in maintaining cardiac output in the setting of a large myocardial
infarction. This compensatory mechanism is lost when multivessel
disease is present and severe enough to produce ischemia in
noninfarct segments.
A series of neurohumoral responses is activated in an attempt
to restore cardiac output and vital organ perfusion. Decreased
32
34
35
have demonstrated the

CHAPTER 13 Postmyocardial Infarction Cardiogenic Shock 141
y congestion
https://t.me/medicina_free
Systemic
IL-6 ⇑
IL-7 ⇓
IL-8 ⇑
IL-10⇑
IF ⇑
G-CSF ⇑
MCP-1 ⇑
MCP-1β ⇑
Fig. 13.1 Prognostically relevant components of cardiogenic shock complicating myocardial
infarction. In addition to severe systolic and diastolic cardiac dysfunction compromising macrocirculation and microcirculation, systemic inflammatory response syndrome and even sepsis may
develop, finally resulting in multiorgan dysfunction syndrome.The proinflammatory and antiinflammatory cytokines mentioned have prognostic significance, with either higher (↑) or lower (↓)
serum levels in nonsurvivors compared with survivors. G-CSF, Granulocyte colony-stimulating
factor; IF, interferon; IL, interleukin; MCP, monocyte chemotactic protein; MIP, macrophage
inflammatory protein; NO, nitric oxide; iNOS, inducible macrophage-type nitric oxide synthase.
(Modified from Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding
the paradigm. Circulation. 2003;107:2998–3002.)
Inflammatory
iNOS
NO
Peroxynitrite
inflammation
cytokines
Vasodilation
SVR
Systemic
perfusion
perfusion pressure
Compensatory
vasoconstriction
Cardiac output
Stroke volume
Hypotension
Coronary
Myocardial infarction
Myocardial dysfunction
Systolic
Pulmonar
Ischemia
Diastolic
LVEDP
Hypoxemia
Progressive
myocardial
dysfunction
Death
baroreceptor activity due to hypotension increases sympathetic
outflow and reduces vagal tone. This increases heart rate, myocardial contractility, venous tone, and arterial vasoconstriction.
Vasoconstriction is most pronounced in the skeletal, splanchnic,
and cutaneous vascular beds to redistribute cardiac output to
the coronary, renal, and cerebral circulations. An increase in the
ratio of precapillary to postcapillary resistance decreases capillary
hydrostatic pressure, facilitating movement of interstitial fluid into
the vascular compartment. Increased catecholamine levels and
decreased renal perfusion lead to renin release and angiotensin
production. Elevated angiotensin levels stimulate peripheral
vasoconstriction and aldosterone synthesis. Aldosterone increases
sodium and water retention by the kidney, raising blood volume.
Release of antidiuretic hormone from the posterior pituitary by
baroreceptor stimulation also increases water retention. Local
autoregulatory mechanisms that decrease arteriolar resistance and
increase regional blood flow are stimulated by hypoxia, acidosis,
and accumulation of vasoactive metabolites (e.g., adenosine).
Enhanced anaerobic metabolism, lactic acidosis, and depleted
adenosine triphosphate (ATP) stores result when compensatory
neurohumoral responses are overwhelmed, further depressing
ventricular function. Arrhythmias may reduce cardiac output and
increase myocardial ischemia as well. Loss of vascular endothelial
integrity because of ischemia culminates in multiorgan failure.
Pulmonary edema impairs gas exchange. Renal and hepatic dysfunction results in fluid, electrolyte, and metabolic disturbances.
Gastrointestinal ischemia can lead to hemorrhage or entry of
bacteria into the bloodstream, causing sepsis. Microvascular
thrombosis due to capillary endothelial damage with fibrin
deposition and catecholamine-induced platelet aggregation
further impairs organ function.
A systemic inflammatory state with high plasma levels of
cytokines (e.g., tumor necrosis factor-α, interleukin-6) and
inappropriate nitric oxide production may also depress myocardial
function or impair catecholamine-induced vasoconstriction,
respectively. All of these factors, in turn, lead to diminished
coronary artery perfusion and thus trigger a vicious cycle of
further myocardial ischemia and necrosis. This results in even
lower blood pressure, lactic acidosis, multiorgan failure, and
ultimately death.
36
CLINICAL PRESENTATION
History and Physical Examination
The diagnosis of acute MI must be confirmed. Noncardiac causes
of shock need to be ruled out; these include aortic dissection,
tension pneumothorax, massive pulmonary embolism, ruptured
viscus, hemorrhage, and sepsis. Risk factors for developing
cardiogenic shock include older age, anterior MI location,
hypertension, diabetes mellitus, multivessel coronary artery
disease, prior MI, prior congestive heart failure, STEMI, or left
bundle branch block.
37,38

142 PART III Coronary Artery Disease
https://t.me/medicina_free
Patients usually appear ashen or cyanotic, with cold and
clammy skin. They may be agitated, disoriented, or lethargic
from cerebral hypoperfusion. The pulses are rapid and faint, the
pulse pressure narrow, and arrhythmias are common. Jugular
venous distention and pulmonary rales are usually present in
left ventricular shock, but may be absent. Jugular venous distention, Kussmaul sign (a paradoxic increase in jugular venous
pressure during inspiration), and absent rales are found in right
ventricular shock. Left ventricular dyskinesis may produce a
precordial heave. A systolic thrill along the left sternal border is
consistent with mitral regurgitation or ventricular septal defect.
The heart sounds are distant. Third and fourth heart sounds or
a summation gallop can be auscultated. The systolic murmur
of mitral regurgitation is often present; ventricular septal defect
also produces a systolic murmur. The absence of a murmur,
however, does not exclude these complications. The extremities
are usually vasoconstricted.
Electrocardiography and Laboratory Testing
A large anterior or anterolateral MI pattern is often present. Old
anterior Q waves or new ST segment elevation in the right
precordial leads consistent with right ventricular MI may be
noted with acute inferior MI. Multiple lead ST segment depression
without an injury current is another pattern that can occur with
multivessel or left main disease. New left bundle branch block
and third-degree atrioventricular conduction block are ominous
findings. A relatively normal ECG should alert one to other
causes of shock.
Troponin and creatine kinase levels are high, may peak late
because of prolonged washout or ongoing necrosis, and can rise
secondarily with infarct extension. Lactic acidosis, hypoxemia,
and mixed venous oxygen desaturation are usually present.
Echocardiography
Echocardiography can be performed rapidly and offers valuable
information on the extent of left ventricular dysfunction. A dilated,
hypokinetic left ventricle suggests left ventricular shock, whereas
a dilated right ventricle suggests right ventricular involvement.
Normal ventricular function, low cardiac output, and mitral
regurgitation are consistent with acute severe mitral regurgitation. Pericardial tamponade from hemorrhagic effusion or free
wall rupture can quickly be detected. Doppler evaluation can
easily confirm the presence of significant mitral regurgitation
or ventricular septal rupture. Transesophageal echo is helpful
in patients for whom image quality is inadequate or when a
flail mitral leaflet is suspected but not seen on transthoracic
echocardiography.
MANAGEMENT
General Measures
A number of supportive measures need to be instituted quickly
(Fig. 13.2). If there is no clinical evidence for pulmonary edema,
a fluid bolus should be given to exclude hypovolemia as a cause
of hypotension. Patients with a history of inadequate fluid
intake, diaphoresis, diarrhea, vomiting, or diuretic use may not
have pump failure and will improve dramatically with fluid
BOX 13.1 Conventional Therapy for
Cardiogenic Shock
1. Maximize volume (RAP 10–14 mm Hg, PAWP 18–20 mm Hg)
2. Maximize oxygenation (e.g., ventilator)
3. Correct electrolyte and acid-base imbalances
4. Control rhythm (e.g., pacemaker, cardioversion)
5. Sympathomimetic amines (e.g., dobutamine, dopamine, norepinephrine)
6. Phosphodiesterase inhibitors (e.g., milrinone)
7. Vasodilators (e.g., nitroglycerin, nitroprusside)
8. Intraaortic balloon counterpulsation
PAWP, Pulmonary artery wedge pressure; RAP, right atrial pressure.
administration. Because preload is critical in patients with right
ventricular shock, fluid support and avoidance of nitrates and
morphine are indicated (Box 13.1).
Oxygenation and airway protection are critical. Intubation
and mechanical ventilation may be required, followed by sedation,
and often muscular paralysis. These interventions also improve
the safety of electrical cardioversion or cardiac catheterization,
if needed, and decrease oxygen demand. Positive end-expiratory
pressure (PEEP) decreases preload and afterload.
Hypokalemia and hypomagnesemia predispose patients to
ventricular arrhythmias and should be corrected. Because metabolic acidosis decreases contractile function, hyperventilation
should be considered, but sodium bicarbonate should be avoided
given its short half-life and the large sodium load.
Arrhythmias and atrioventricular heart block have a major
influence on cardiac output. Atrial and ventricular tachyarrhythmias should be electrically cardioverted promptly rather
than treated with pharmacologic agents. Severe bradycardia due
to excess vagotonia can be corrected with atropine. Temporary
pacing should be initiated for high-degree heart block, preferably
with a dual-chamber system. This is especially important in
patients with right ventricular infarction who depend on the
right atrial contribution to preload.
Aspirin and monitored unfractionated heparin should be
administered to decrease the likelihood of reinfarction, ventricular
mural thrombus formation, or deep venous thrombosis in the
setting of low flow and hypercoagulability. Platelet P2Y
receptor
12
inhibitors (clopidogrel, prasugrel, ticagrelor) are best withheld
until cardiac catheterization has determined the need for emergency surgery because of their prolonged action and increased
risk for perioperative bleeding. Morphine sulfate decreases pain
and anxiety, excessive sympathetic activity, preload, and afterload,
but should only be administered in small increments. Diuretics
decrease filling pressures and should be used to control volume.
Beta-blockers and calcium channel blockers should be avoided
because they are negative inotropic agents. An insulin infusion
may be required to control hyperglycemia.
Hemodynamic Monitoring
Central hemodynamic monitoring is critical for confirming the
diagnosis and guiding pharmacologic therapy (Table 13.2). Urine
output needs to be monitored hourly through catheter drainage.
An arterial catheter allows constant monitoring of the blood
pressure. A pulmonary artery catheter should be inserted as soon

CHAPTER 13 Postmyocardial Infarction Cardiogenic Shock 143
1st line
of action
2nd line
of action
3r
of action
https://t.me/medicina_free
Clinical signs: Shock, hypoperfusion, congestive
heart failure, acute pulmonary edema
Most likely major underlying disturbance?
Acute
pulmonary
edema
Administer
• Furosemide IV 0.5 to
1.0 mg/kg*
• Morphine IV 2 to 4 mg
• Oxygen/intubation as
needed
• Nitroglycerin SL, then
10 to 20 μg/min IV if
SBP greater than 100
mm Hg
Dopamine 5 to 15 μg/
•
kg per minute IV if SBP
70 to 100 mm Hg and
signs/symptoms of
shock present
•
Dobutamine 2 to 20 μg/
kg per minute IV if SBP
70 to 100 mm Hg and no
signs/symptoms of shock
Check blood
pressure
Systolic BP
Greater than 100
mm Hg and not less
than 30 mm Hg
below baseline
Hypovolemia
Administer
• Fluids
• Blood transfusions
• Cause-specific
interventions
Consider
vasopressors
Systolic BP
Greater than
100 mm Hg
Low-output
cardiogenic
Check blood
pressure
Systolic BP
70 to 100
mm Hg
No signs/
symptoms
of shock
shock
Arrhythmia
Bradycardia
See Section 7.7
in the full-text
Guidelines
Systolic BP
70 to 100 mm Hg
Signs/symptoms
of shock
Tachycardia
Systolic BP
Less than
70 mm Hg
Signs/symptoms
of shock
d line
Fig. 13.2 Emergency management of complicated ST-elevation myocardial infarction. ACE,
Angiotensin-converting enzyme; BP, blood pressure; IV, intravenous; MI, myocardial infarction;
SBP, systolic blood pressure; SL, sublingual. (From Antman EM, Anbe DT, Armstrong PW, et al.
ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a
report of the American College of Cardiology/American Heart Association Task Force on Practice
Guidelines. Circulation. 2004;110;e82.)
ACE inhibitors
• Short-acting agent
such as captopril
(1 to 6.25 mg)
Nitroglycerin
• 10 to 20 μg/
min IV
Further diagnostic/therapeutic considerations
(should be considered in nonhypovolemic shock)
• Pulmonary artery catheter
• Echocardiography
• Angiography for MI/ischemia
• Additional diagnostic studies
Dobutamine
• 2 to 20 μg/kg
per minute IV
Diagnostic
Dopamine
• 5 to 15 μg/kg
per minute IV
Intraaortic balloon pump
Reperfusion/
revascularization
Norepinephrine
• 0.5 to 30 μg/
min IV
Therapeutic
Соседние файлы в папке Библиотека им академика М.И. Перельмана
